(VIANEWS) – Shares of ULTIMOVACS (Oslo Børs Benchmark Index_GI: ULTI.OL) fell by a staggering 34.14% in 21 sessions from kr123.6 to kr81.40 at 05:39 EST on Tuesday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is sliding 1.13% to kr1,231.97, following the last session’s downward trend.
ULTIMOVACS’s last close was kr81.40, 42.92% below its 52-week high of kr142.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-4.72.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.74%.
Moving Average
ULTIMOVACS’s worth is way below its 50-day moving average of kr121.07 and way below its 200-day moving average of kr102.27.
Volatility
ULTIMOVACS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.09%, a negative 2.68%, and a positive 2.47%.
ULTIMOVACS’s highest amplitude of average volatility was 0.95% (last week), 3.63% (last month), and 2.47% (last quarter).
Volume
Today’s last reported volume for ULTIMOVACS is 170498 which is 161.47% above its average volume of 58081.
More news about ULTIMOVACS (ULTI.OL).
